Literature DB >> 34964937

Imaging Histamine H3 Receptors with Positron Emission Tomography.

Pablo Martín Rusjan1,2, Bernard Le Foll3,4,5,6,7,8,9.   

Abstract

Positron emission tomography (PET) provides a unique tool to study the biochemistry of the human brain in vivo. By using PET probes that are binding selectively to certain receptor subtypes, brain PET allows the quantification of receptor levels in various brain areas of human subjects. This approach has the potential to reveal abnormal receptor expressions that may contribute to the physiopathology of some psychiatric and neurological disorders. This approach also has the potential to assist in the drug development process by determining receptor occupancy in vivo allowing selection of proper drug dosage to produce therapeutic effects. Several PET tracers have been developed for histamine H3 receptors (H3R). However, despite the potential of PET to elucidate the role of H3R in vivo, only limited work has been conducted so far. This article reviews the work that has been done in this area. Notably, we will cover the limitations of the first-generation PET radioligand for H3R and present the advantages of novel radioligands that promise an explosion of clinical PET research on the role of H3R in vivo.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Histamine H3 receptors; Human brain; Pitolisant; Positron emission tomography; Receptor occupancy study; [11C]GSK189254; [11C]MK8278; [11C]TASP457; [18F]FMH3

Mesh:

Substances:

Year:  2022        PMID: 34964937     DOI: 10.1007/7854_2021_285

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  38 in total

1.  Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol.

Authors:  Bradley T Christian; Tanjore Narayanan; Bing Shi; Evan D Morris; Joseph Mantil; Jogeshwar Mukherjee
Journal:  J Cereb Blood Flow Metab       Date:  2004-03       Impact factor: 6.200

2.  Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study.

Authors:  Peter S Bloomfield; Sudhakar Selvaraj; Vincenzo de Paola; Oliver D Howes; Mattia Veronese; Gaia Rizzo; Alessandra Bertoldo; David R Owen; Michael Ap Bloomfield; Ilaria Bonoldi; Nicola Kalk; Federico Turkheimer; Philip McGuire
Journal:  Am J Psychiatry       Date:  2015-10-16       Impact factor: 18.112

3.  Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD.

Authors:  Michael Egan; Roy Yaari; Lian Liu; Michael Ryan; Yahong Peng; Christopher Lines; David Michelson
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

4.  Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited.

Authors:  Vincent J Cunningham; Eugenii A Rabiner; Mark Slifstein; Marc Laruelle; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-09       Impact factor: 6.200

5.  Quantification of PET studies with the very high-affinity dopamine D2/D3 receptor ligand [11C]FLB 457: re-evaluation of the validity of using a cerebellar reference region.

Authors:  Marie-Claude Asselin; Andrew J Montgomery; Paul M Grasby; Susan P Hume
Journal:  J Cereb Blood Flow Metab       Date:  2006-05-24       Impact factor: 6.200

6.  Test-retest reproducibility of [(11)C]PBR28 binding to TSPO in healthy control subjects.

Authors:  K Collste; A Forsberg; A Varrone; N Amini; S Aeinehband; I Yakushev; C Halldin; L Farde; S Cervenka
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-22       Impact factor: 9.236

7.  Unexpectedly high affinity of a novel histamine H(3) receptor antagonist, GSK239512, in vivo in human brain, determined using PET.

Authors:  S Ashworth; A Berges; E A Rabiner; A A Wilson; R A Comley; R Y K Lai; R Boardley; G Searle; R N Gunn; M Laruelle; V J Cunningham
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

8.  Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET.

Authors:  Sharon Ashworth; Eugenii A Rabiner; Roger N Gunn; Christophe Plisson; Alan A Wilson; Robert A Comley; Robert Y K Lai; Antony D Gee; Marc Laruelle; Vincent J Cunningham
Journal:  J Nucl Med       Date:  2010-06-16       Impact factor: 10.057

9.  Use of PET and the radioligand [carbonyl-(11)C]WAY-100635 in psychotropic drug development.

Authors:  B Andrée; C Halldin; S O Thorberg; J Sandell; L Farde
Journal:  Nucl Med Biol       Date:  2000-07       Impact factor: 2.408

10.  Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor.

Authors:  J M Arrang; M Garbarg; J C Schwartz
Journal:  Nature       Date:  1983-04-28       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.